×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GDTC – cytomed therapeutics limited - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GDTC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
07:00 am
gdtc
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
Medium
Report
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
10/10
09:36 am
gdtc
CytoMed Therapeutics Limited (NASDAQ: GDTC) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $5.00 price target on the stock.
Neutral
Report
CytoMed Therapeutics Limited (NASDAQ: GDTC) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $5.00 price target on the stock.
10/7
07:00 am
gdtc
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
Medium
Report
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
10/3
07:00 am
gdtc
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
Low
Report
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
9/30
07:00 am
gdtc
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
Low
Report
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/20
07:00 am
gdtc
Form 6-K CytoMed Therapeutics For: Nov 20
Medium
Report
Form 6-K CytoMed Therapeutics For: Nov 20
11/4
12:14 pm
gdtc
Form 144 CytoMed Therapeutics Filed by: mDR Ltd
Low
Report
Form 144 CytoMed Therapeutics Filed by: mDR Ltd
10/7
07:45 am
gdtc
Form 6-K CytoMed Therapeutics For: Oct 07
Medium
Report
Form 6-K CytoMed Therapeutics For: Oct 07
10/3
07:00 am
gdtc
Form 6-K CytoMed Therapeutics For: Oct 03
Low
Report
Form 6-K CytoMed Therapeutics For: Oct 03
9/30
07:00 am
gdtc
Form 6-K CytoMed Therapeutics For: Sep 30
Low
Report
Form 6-K CytoMed Therapeutics For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: